Carlos Amaya-Chanaga, MD

Pharmacyclics LLC, an AbbVie Company
999 E Arques Ave.
Sunnyvale, CA
USA 94085
Papers:
1863 A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions
1864 Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma Cytokine Levels
1872 Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLLTM Real-World Registry
4425 Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLLTM Real-World Registry